ExodusPoint Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

ExodusPoint Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-34,141	Closed	-$18K	–	2222
2022 Q4	$18K	Buy	34,141 +19,588	+135%	+$12.4K	﹤0.01%	1568
2022 Q3	$11K	Sell	14,553 -3,376	-19%	-$3.83K	﹤0.01%	1817
2022 Q2	$20K	Sell	17,929 -6,796	-27%	-$8.65K	﹤0.01%	1852
2022 Q1	$51K	Sell	24,725 -22,934	-48%	-$54.5K	﹤0.01%	2061
2021 Q4	$137K	Buy	47,659 +24,193	+103%	+$89.5K	﹤0.01%	1901
2021 Q3	$99K	Sell	23,466 -20,681	-47%	-$92.3K	﹤0.01%	1907
2021 Q2	$234K	Buy	44,147 +26,100	+145%	+$125K	﹤0.01%	1896
2021 Q1	$84K	Buy	+18,047	New	+$81.8K	﹤0.01%	1997
2020 Q3	–	Sell	-165,731	Closed	-$559K	–	2347
2020 Q2	$559K	Buy	+165,731	New	+$784K	0.01%	1024
2020 Q1	–	Sell	-13,290	Closed	-$80K	–	1782
2019 Q4	$80K	Buy	+13,290	New	+$90.9K	﹤0.01%	1444

Other funds holding ZYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ExodusPoint Capital Management's ZYNE Position: Q1 2023 in Review

ExodusPoint Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2023, closing a stake of 34,141 shares — an estimated $18K sold.

ExodusPoint Capital Management first reported a position in ZYNE in Q4 2019 and held it in 10 quarters. The position peaked at $559K in Q2 2020. 44 funds tracked by Wall St. Rank hold ZYNE as of Q1 2023.

ExodusPoint Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 34,141 Zynerba Pharmaceuticals, Inc shares in Q1 2023, an estimated $18K.
ExodusPoint Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2019 and held it in 10 quarters.
ExodusPoint Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $559K in Q2 2020.
44 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2023.

Based on ExodusPoint Capital Management's 13F filing for Q1 2023, filed 11 May 2023.